Literature DB >> 18234553

Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction.

D Kelly1, S Khan, G Cockerill, L L Ng, M Thompson, N J Samani, I B Squire.   

Abstract

INTRODUCTION: Changes to cardiac matrix are central to ventricular remodelling after acute MI and matrix metalloproteinase expression is implicated in this process. We investigated the temporal profile of MMP-3 and its relationship to LV dysfunction and prognosis following AMI.
METHODS: We studied 382 patients with AMI. Plasma MMP-3 was measured at 0-12, 12-24 h and for subsequent 24 h periods during admission. LV function (LVEF) was assessed by echocardiography pre-discharge and at a median of 148 days and clinical endpoints at a median of 313 days.
RESULTS: MMP-3 peaked prior to discharge thus pre-discharge levels were used in analyses. MMP-3 was associated with patient age (p<0.001), creatinine (p<0.001) and was higher in males (p<0.001) and hypertensives (p<0.001). MMP-3 inversely correlated with LVEF at follow-up (p=0.043), was higher in subjects with LVEF <40% (p=0.017) and in subjects with increasing EDV (p=0.017) or ESV (p=0.007) compared to those in whom volumes fell between visits. In the 58 patients reaching the endpoint of death or heart failure, MMP-3 was higher (p<0.001). On Kaplan-Meier analysis, subjects with levels above optimum cut off identified via ROC curves were more likely to suffer a clinical event (p=0.037).
CONCLUSION: MMP-3 is associated with left ventricular dysfunction, adverse left ventricular remodelling and prognosis after AMI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234553      PMCID: PMC2635532          DOI: 10.1016/j.ejheart.2007.12.009

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  20 in total

1.  Regression of left ventricular hypertrophy after surgical therapy for aortic stenosis is associated with changes in extracellular matrix gene expression.

Authors:  T Walther; A Schubert; V Falk; C Binner; A Kanev; S Bleiziffer; C Walther; N Doll; R Autschbach; F W Mohr
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

2.  MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition.

Authors:  H Li; H Simon; T M Bocan; J T Peterson
Journal:  Cardiovasc Res       Date:  2000-05       Impact factor: 10.787

Review 3.  Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.

Authors:  M A Pfeffer; E Braunwald
Journal:  Circulation       Date:  1990-04       Impact factor: 29.690

4.  Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function.

Authors:  F G Spinale; M L Coker; C V Thomas; J D Walker; R Mukherjee; L Hebbar
Journal:  Circ Res       Date:  1998-03-09       Impact factor: 17.367

5.  Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

Authors:  Merry L Lindsey; Joseph Gannon; Masanori Aikawa; Frederick J Schoen; Elena Rabkin; Lori Lopresti-Morrow; Jamie Crawford; Shawn Black; Peter Libby; Peter G Mitchell; Richard T Lee
Journal:  Circulation       Date:  2002-02-12       Impact factor: 29.690

6.  Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction.

Authors:  Frédérique Mizon-Gérard; Pascal de Groote; Nicolas Lamblin; Xavier Hermant; Jean Dallongeville; Philippe Amouyel; Christophe Bauters; Nicole Helbecque
Journal:  Eur Heart J       Date:  2004-04       Impact factor: 29.983

7.  Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction.

Authors:  H D White; R M Norris; M A Brown; P W Brandt; R M Whitlock; C J Wild
Journal:  Circulation       Date:  1987-07       Impact factor: 29.690

8.  Myocardial infarct expansion and matrix metalloproteinase inhibition.

Authors:  Rupak Mukherjee; Theresa A Brinsa; Kathryn B Dowdy; Amelia A Scott; Julia M Baskin; Anne M Deschamps; Abigail S Lowry; G Patricia Escobar; David G Lucas; William M Yarbrough; Michael R Zile; Francis G Spinale
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

9.  Plasma MMP-9 and MMP-2 following acute myocardial infarction in man: correlation with echocardiographic and neurohumoral parameters of left ventricular dysfunction.

Authors:  Iain B Squire; Jon Evans; Leong L Ng; Ian M Loftus; Matt M Thompson
Journal:  J Card Fail       Date:  2004-08       Impact factor: 5.712

10.  Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study.

Authors:  Dominic Kelly; Gillian Cockerill; Leong L Ng; Matt Thompson; Sohail Khan; Nilesh J Samani; Iain B Squire
Journal:  Eur Heart J       Date:  2007-03-05       Impact factor: 29.983

View more
  31 in total

1.  Matrix metalloproteinase therapy in heart failure.

Authors:  Francis G Spinale; Nikole M Wilbur
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-08

Review 2.  Tissue inhibitor of metalloproteinases (TIMPs) in heart failure.

Authors:  Linn Moore; Dong Fan; Ratnadeep Basu; Vijay Kandalam; Zamaneh Kassiri
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

3.  Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia.

Authors:  Justin P Zachariah; Steven D Colan; Peter Lang; John K Triedman; Mark E Alexander; Edward P Walsh; Charles I Berul; Frank Cecchin
Journal:  Circ Heart Fail       Date:  2012-05-24       Impact factor: 8.790

4.  Tissue plasminogen activator antigen predicts medium-term left ventricular end-systolic volume after acute myocardial infarction.

Authors:  Robin A P Weir; Sean Balmain; Tracey Steedman; Leong L Ng; Iain B Squire; Anne Rumley; Henry J Dargie; Gordon D O Lowe
Journal:  J Thromb Thrombolysis       Date:  2010-05       Impact factor: 2.300

5.  Simultaneous consideration of multiple candidate protein biomarkers for long-term risk for cardiovascular events.

Authors:  Sharif A Halim; Megan L Neely; Karen S Pieper; Svati H Shah; William E Kraus; Elizabeth R Hauser; Robert M Califf; Christopher B Granger; L Kristin Newby
Journal:  Circ Cardiovasc Genet       Date:  2014-11-24

Review 6.  Biomarkers in acute myocardial infarction.

Authors:  Daniel Chan; Leong L Ng
Journal:  BMC Med       Date:  2010-06-07       Impact factor: 8.775

Review 7.  Matrix metalloproteinases: drug targets for myocardial infarction.

Authors:  Andriy Yabluchanskiy; Yaojun Li; Robert J Chilton; Merry L Lindsey
Journal:  Curr Drug Targets       Date:  2013-03       Impact factor: 3.465

Review 8.  Understanding cardiac extracellular matrix remodeling to develop biomarkers of myocardial infarction outcomes.

Authors:  Signe Holm Nielsen; Alan J Mouton; Kristine Y DeLeon-Pennell; Federica Genovese; Morten Karsdal; Merry L Lindsey
Journal:  Matrix Biol       Date:  2017-12-14       Impact factor: 11.583

9.  Protein/polysaccharide-based scaffolds mimicking native extracellular matrix for cardiac tissue engineering applications.

Authors:  Elisabetta Rosellini; Yu Shrike Zhang; Bianca Migliori; Niccoletta Barbani; Luigi Lazzeri; Su Ryon Shin; Mehmet Remzi Dokmeci; Maria Grazia Cascone
Journal:  J Biomed Mater Res A       Date:  2017-11-20       Impact factor: 4.396

10.  Structural and biomechanical characterizations of porcine myocardial extracellular matrix.

Authors:  Bo Wang; Mary E Tedder; Clara E Perez; Guangjun Wang; Amy L de Jongh Curry; Filip To; Steven H Elder; Lakiesha N Williams; Dan T Simionescu; Jun Liao
Journal:  J Mater Sci Mater Med       Date:  2012-05-15       Impact factor: 3.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.